Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Thank You AntiMarv, That's good and the associated epitome spreading is good. I know they are using MAGE-A4, PRAME, NY-ESO-1, etc.
If you can reactivate the endogenous immune system, and also add additional antigen targets for each specific cancer, it has to be more beneficial, I just don't know if the improvement will be so much better as to justify starting a new trial.

I'll leave that up to MRKR, they will do the right thing.